July 7, 2017 10:02 AM EDTUpdated 10:14 AM
Peer Review

Ex-Alex­ion CEO Hal­lal named chair­man at Schol­ar Rock; Ad­vax­is CEO O'­Con­nor is out

Shehla Shakoor

Managing Director

⇨ David Hal­lal has a new po­si­tion as chair­man at Schol­ar Rock. The ex-Alex­ion CEO found him­self in the news late last year when sales of their top 10 most ex­pen­sive drug Soliris be­came the spot­light of an in­ter­nal fraud in­ves­ti­ga­tion, step­ping down soon af­ter for “per­son­al rea­sons.” The le­gal muck has cast a shad­ow on CEO Lud­wig Han­son’s quest to re­struc­ture Alex­ion, HHS is now on it’s tail.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ex­clu­sive: In $1B+ bet on AI, bio­phar­ma heavy­weights back new start­up to up­end drug R&D

Ex­clu­sive: Marc Tessier-Lav­i­gne on leav­ing Stan­ford and join­ing biotech’s new AI mega-start­up

Why VC leg­end Bob Nelsen is mak­ing the biggest ini­tial bet of his 37-year ca­reer on Xaira

No­var­tis’ sim­pli­fied strat­e­gy takes shape as the com­pa­ny seeks for­mer Bris­tol My­ers CEO as chair

FDA gives ac­cel­er­at­ed ap­proval to Day One’s tar­get­ed treat­ment for most com­mon brain tu­mor in kids

No­var­tis will change CRO re­la­tion­ships ‘over time’ as Sen­ate bill tar­get­ing Chi­nese com­pa­nies looms

A service from the Financial Times